Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Neutral +5

Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance

AI-generated analysis

πŸ“ˆ Gilead Sciences (GILD) stock closed at $139.37, gaining 2.22% but lagging the broader market indices like the S&P 500 and Nasdaq.

πŸ“‰ Despite today's gain, shares have depreciated by 9.12% over the past month while slightly outperforming the Medical sector.

πŸ’° Analysts predict earnings per share (EPS) of $1.86 for the upcoming quarter, representing a 2.76% growth year-over-year.

πŸ’΅ Revenue is forecasted at $6.86 billion for the current quarter, indicating a 2.93% increase compared to last year.

πŸ“… Full-year earnings are projected at $8.66 per share with revenue of $30.18 billion, showing moderate growth expectations.

πŸ“Š The Zacks Consensus EPS estimate has remained unchanged recently, while the company currently holds a Zacks Rank of #3 (Hold).

πŸ’‘ Investors are advised to monitor changes in analyst estimates as these often correlate with stock price performance.

πŸ“‰ Gilead is trading at a Forward P/E ratio of 15.75, which is lower than the industry average of 17.84.

πŸ”„ The PEG ratio stands at 1.79, higher than the Medical - Biomedical and Genetics industry average of 1.49, reflecting current valuation metrics.

πŸ₯ Gilead belongs to an industry group ranked in the bottom 40% out of all 250+ industries according to Zacks Industry Rank.

πŸ“‰ Historically, top-ranked industries tend to outperform lower-rated ones by a factor of 2 to 1 based on Zacks research.

πŸ“ˆ The Zacks #1 Strong Buy rank has historically delivered an average annual return of +25% since 1988, according to external audits.

Bullish Signals
  • Gilead Sciences stock closed at $139.37, gaining +2.22% on the most recent trading day.
  • The company's shares outperformed the broader Medical sector, which lost 9.63% over the past month compared to Gilead's 9.12% decline.
  • Analysts predict a year-over-year EPS growth of 2.76% for the upcoming earnings disclosure.
  • Revenue is expected to grow by 2.93% from the same quarter last year, with consensus estimates at $6.86 billion.
  • Full-year Zacks Consensus Estimates project a 6.26% increase in earnings per share and a 2.5% rise in revenue compared to the prior year.
  • Gilead Sciences is currently trading at a Forward P/E ratio of 15.75, which represents a discount relative to its industry average of 17.84.
  • The Zacks Rank #3 (Hold) has a track record with Zacks Rank #1 stocks delivering an average annual return of +25% since 1988.
Risk Factors
  • Gilead Sciences shares have depreciated by 9.12% over the past month, trailing the broader S&P 500's decline of only 7.64%.
  • The stock currently holds a Zacks Rank of #3 (Hold), which is below the top-performing ranks that historically deliver superior returns.
  • Gilead trades at a PEG ratio of 1.79, which is significantly higher than the industry average of 1.49, potentially indicating the stock is overvalued relative to its growth.
  • The Medical - Biomedical and Genetics industry ranks in the bottom 40% of all industries according to Zacks Industry Rank metrics.
  • Analyst consensus estimates for earnings remain unchanged over the last 30 days, suggesting a lack of optimism or positive momentum driving valuation increases.
  • Gilead's stock price lagged both the S&P 500 and the Nasdaq during strong market gains, indicating underperformance relative to broader market trends.
Full Analysis
Gilead Sciences stock closed at $139.37, representing a 2.22% gain from the previous session, though this underperformed the broader market as the S&P 500 rose 2.91%. Over the past month, GILD shares have depreciated by 9.12%, which was a better performance than the Medical sector's loss of 9.63% but lagged behind the S&P 500's decline of 7.64%. Investors will be closely watching the company for its upcoming earnings disclosure, where analysts project earnings per share (EPS) of $1.86 and revenue of $6.86 billion. These figures indicate growth of 2.76% and 2.93%, respectively, compared to the same quarter last year. For the full year, consensus estimates forecast EPS of $8.66 per share and revenue of $30.18 billion, reflecting year-over-year growth projections of +6.26% and +2.5%. Recent analyst estimate adjustments have remained unchanged over the last 30 days regarding EPS expectations, a factor incorporated into the Zacks Rank system which currently rates Gilead Sciences as #3 (Hold). Historically, stocks with a #1 rank have delivered an average annual return of +25% since 1988, suggesting that tracking estimate changes can offer actionable insights for performance relative to expectations. Valuation metrics show Gilead Sciences trading at a Forward P/E ratio of 15.75, which represents a discount compared to the industry average of 17.84. The company also trades at a price-to-earnings-growth (PEG) ratio of 1.79, higher than the Medical - Biomedical and Genetics industry average of 1.49. This industry holds a Zacks Industry Rank of 148, placing it in the bottom 40% out of over 250 industries analyzed, though research indicates that top-rated industries tend to outperform the bottom half by a factor of 2 to 1.